Eugene Huang, chairman, and Hua-Lin Wu, consultant of Blue Blood Biotech Corp., provide insightful information on BB-101, a protein proven to be efficient for wound healing, while sharing their vision for the future growth of the company through partnerships with big pharmaceutical companies.
Could you introduce yourself to our executive readership?
"BB-101 is the first new protein drug, with its progression from drug discovery, R&D, preclinical study to clinical trials carried out independently by a domestic biotech company in Taiwan."
